Pediatric Acute Myeloid Leukemia: Improved Survival Rates in India

Seth, Rachna; Pathak, Nivedita; Singh, Amitabh; Chopra, Anita; Kumar, Rajive; Kalaivani, Mani

doi:10.1007/s12098-016-2234-8

Cited by 3 publications

(10 citation statements)

References 6 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A total of 1,210 patients were included from the 19 studies. 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 Three of the 19 studies also included patients with acute promyelocytic leukemia (APML). 19 21 22 Eight studies were published before 2015, while the remaining 11 studies were published in or after 2015.…”

Section: Resultsmentioning

confidence: 99%

“…8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 Three of the 19 studies also included patients with acute promyelocytic leukemia (APML). 19 21 22 Eight studies were published before 2015, while the remaining 11 studies were published in or after 2015. The various studies included patients between 1 and 19 years of age.…”

Section: Resultsmentioning

confidence: 99%

“…Data regarding induction chemotherapy were available from 17 studies. 8 9 11 12 13 14 15 16 17 18 19 20 21 22 23 25 26 Anthracycline-based regimens were used for induction in all studies. 3 + 7 regimen consisting of daunorubicin (45–60 mg/m 2 /day) and cytarabine (100–200 mg/m 2 /day) was the standard regimen used in nine studies, while MRC AML based regimens that included an additional third agent (etoposide) were used in seven studies.…”

Section: Resultsmentioning

confidence: 99%

“…Data for OS was available from 16 studies. 8 9 10 11 13 14 15 16 17 18 19 20 21 23 24 25 Philip et al reported an OS of 70% with a follow-up of 7 months. Remaining 15 studies had OS ranging between 15 and 66%.…”

Section: Resultsmentioning

confidence: 99%

See 3 more Smart Citations

Pediatric Acute Myeloid Leukemia in India: A Systematic Review

Srinivasan

Gollamudi

Dhariwal

2022

Indian J Med Paediatr Oncol

View full text Add to dashboard Cite

Background Lower-middle-income countries face unique problems in the management of pediatric acute myeloid leukemia (AML) due to which the outcomes have not kept pace with developed nations. In India, data on childhood AML is sparsely available, thus making a true assessment of disease trends difficult. The current systematic review was undertaken to assess the outcomes of childhood AML from published literature from India over a period of 10 years (2011–2021). Materials and Methods A systematic search of MEDLINE, Google Scholar, and SCOPUS was performed as per preferred reporting items for systematic reviews and meta-analyses (PRISMA) statement from January 1, 2011 to December 31, 2021. In addition, International Society of Pediatric Oncology (SIOP) conference abstracts were also screened for relevant studies on AML from India. This study was registered in PROSPERO (ID42021273218). Results A total of 1,210 patients from 19 studies were included. Standard 3 + 7 and MRC AML based regimens were commonly adopted regimens for induction. Remission rates varied between 56 and 95%. Overall treatment-related mortality across studies was 23.2% (95% confidence interval [CI]: 10.3–35.9%). The mean incidence of treatment abandonment was 19.3% ( 95% CI: 10.9–27.5%). Event-free survival and overall survival were in the range of 28 to 55% and 15 to 66%, respectively. Hematopoietic stem cell transplantation was performed only on a small subset of patients. Conclusion Outcomes of pediatric AML in India continue to be suboptimal with high treatment abandonment and toxic deaths. Ensuring uniform access to therapy and supportive care along with a robust social support system would improve outcomes of childhood AML in India.

show abstract

Section: Resultsmentioning

confidence: 99%

Section: Resultsmentioning

confidence: 99%

Section: Resultsmentioning

confidence: 99%

Section: Resultsmentioning

confidence: 99%

See 2 more Smart Citations

Pediatric Acute Myeloid Leukemia in India: A Systematic Review

Srinivasan

Gollamudi

Dhariwal

2022

Indian J Med Paediatr Oncol

View full text Add to dashboard Cite

show abstract

“…[13] With improvement is supportive care and standardization of treatment protocols, improved survival has also been reported in pediatric AML management in India. [14] Abandonment of therapy is common in the Indian/low middle income country scenario. Socioeconomic factors and long-term morbidity associated with DS also play part in failure to complete therapy in AML.…”

Section: Discussionmentioning

confidence: 99%

Treating acute myeloid leukemia among children with down syndrome

Kapoor

Mohan

Pramanik

et al. 2020

Indian Journal of Medical and Paediatric Oncology

View full text Add to dashboard Cite

Background: Down Syndrome (DS) children with acute myeloid leukemia (AML) have unique differences in clinical features, epidemiologic nature, and biologic patterns of disease compared with AML in children without DS. Aims and Objective: AML in DS children should be considered distinct disorder from AML in Non DS population and treatment needs to be customized for this population. In this retrospective study spanning from 2014 to 2019 we present our experience of managing leukemia in children with DS. Materials and Methods: From 2014 and 2019, 72 children aged below 18 years were managed at our institute with acute myeloid leukemia (AML). Out of these 72 children with AML, 7 children were with DS which was confirmed by karyotyping. Majority of these children had M7 while M2 and M4 subtypes were seen in one child each. On conventional karyotyping in addition to trisomy 21 additional cytogenetic abnormalities were seen in 4 patients. Two children had trisomy 8. One child had deletion of 11 chromosomes and one had translocation between 8 and 21 chromosomes. Results: All 7 children were administered intensive chemotherapy with curative intent after informed parental consent. All 7 children achieved complete remission. Four out of 7 children had complications related to severe neutropenia. Conclusion: All patients of DS with AML should be offered chemotherapy with curative intent. Endeavour should be to give less aggressive chemotherapy protocol to bring down treatment related mortality.

show abstract

Untitled

2022

Indian J Med Paediatr Oncol

View full text Add to dashboard Cite

Background Lower-middle-income countries face unique problems in the management of pediatric acute myeloid leukemia (AML) due to which the outcomes have not kept pace with developed nations. In India, data on childhood AML is sparsely available, thus making a true assessment of disease trends difficult. The current systematic review was undertaken to assess the outcomes of childhood AML from published literature from India over a period of 10 years (2011)(2012)(2013)(2014)(2015)(2016)(2017)(2018)(2019)(2020)(2021). Materials and Methods A systematic search of MEDLINE, Google Scholar, and SCOPUS was performed as per preferred reporting items for systematic reviews and meta-analyses (PRISMA) statement from January 1, 2011 to December 31, 2021. In addition, International Society of Pediatric Oncology (SIOP) conference abstracts were also screened for relevant studies on AML from India. This study was registered in PROSPERO (ID42021273218). Results A total of 1,210 patients from 19 studies were included. Standard 3 þ 7 and MRC AML based regimens were commonly adopted regimens for induction. Remission rates varied between 56 and 95%. Overall treatment-related mortality across studies was 23.2% (95% confidence interval [

show abstract

Pediatric Acute Myeloid Leukemia: Improved Survival Rates in India

Cited by 3 publications

References 6 publications

Pediatric Acute Myeloid Leukemia in India: A Systematic Review

Pediatric Acute Myeloid Leukemia in India: A Systematic Review

Treating acute myeloid leukemia among children with down syndrome

Untitled

Contact Info

Product

Resources

About